Quest Diagnostics Incorporated (NYSE: DGX), the Secaucus, New Jersey-based provider of diagnostic testing, information, and services, has delivered a strong 2026, climbing roughly 35% year to date. After a recent pullback from its 52-week high, the central question facing investors is whether the shares can extend their run toward a $260 stock price target.
Roughly 17 to 20 Wall Street analysts actively track Quest Diagnostics. The full range of current 12-month price targets spans approximately $232 on the low end to $265 at the high end, with an overall average near $251 and a median around $250. Because that all-targets average sits only about 7% above the recent share price — below a meaningful 10% threshold — the $260 central target used here reflects the average of the analyst targets that sit above the current price, rounded to a clean level.
The dispersion tells the story. On the bullish side, Bank of America carries a $265 target, while Barclays, Truist, Morgan Stanley, and Argus Research each stand at $260; Baird sits at $255, JPMorgan at $250, and Jefferies and UBS at $245. The contrast between the $245-$265 cluster and the low-$230s reflects competing views on how much Quest's premium valuation can expand versus how much reimbursement and margin risk may compress it. Several firms raised targets after second-quarter results — Barclays lifted its target to $260, BofA to $265, and JPMorgan to $250 — signaling a broadly constructive, if not unanimous, shift.
Quest Diagnostics closed around $235 in mid-October 2026, down from a 52-week high of $248.84 set in late September and well above its 52-week low near $171. Reaching $260 implies roughly a 10.6% gain — a modest move for a large-cap healthcare name over a typical research horizon, but one that would require clearing the stock's prior record high and establishing new territory.
The path toward that level depends on execution. Quest beat second-quarter estimates by a wide margin and raised full-year 2026 guidance to net revenue of roughly $11.78 billion to $11.90 billion and reported EPS (earnings per share) of about $9.58 to $9.78. Wall Street models roughly $11.19 in 2026 EPS and about $12.06 in 2027. At a forward P/E (price-to-earnings ratio) near 20x, continued earnings growth rather than multiple expansion would likely need to carry much of the required move.
Several verified developments underpin the bullish case. Quest's consumer-initiated testing business — roughly $300 million in revenue growing around 30% and expected to expand more than 20% annually over the next three to five years — offers a higher-margin growth engine. Its Haystack MRD (minimal residual disease) test recently reported high accuracy in detecting residual and recurrent solid-tumor cancers, supporting a longer-term oncology opportunity. The company also distributes the FDA-approved Shield blood-based colorectal cancer screening test through its nationwide network and introduced the Quest AI Companion in its MyQuest app. Quest's defensive, non-cyclical positioning within healthcare services has made it a favored "safe-haven" name among large diagnostic labs.
The principal obstacles are policy, cost, and valuation. Medicare reimbursement pressure remains a persistent overhang for the diagnostic testing industry, and labor and supply-cost inflation could weigh on margins even as volumes grow. With a trailing P/E near 25x, the stock already commands a premium to much of the healthcare-services sector, leaving limited room for multiple expansion if earnings momentum stalls. Competition from Labcorp and other national laboratories is intense, and analyst targets as low as the $230s show that not every firm believes the current valuation is fully justified.
Technically, $248.84 — the late-September record — is the first meaningful resistance level the stock must reclaim and hold before $260 becomes reachable. The shares have pulled back to roughly $235, near their 50-day moving average (around $233) but still well above the 200-day moving average near $209, indicating an intact longer-term uptrend. Support appears concentrated in the $230 to $233 zone, while $260 itself represents a psychological round number that has not yet been tested.
Analyst price targets typically reflect a 12-month research horizon, though individual firms vary. The nearest catalyst is Quest's third-quarter earnings report, scheduled for late October 2026, which will test whether the company sustains its beat-and-raise pattern. Investors should also monitor any changes to 2026 guidance, revisions to analyst price targets, Medicare reimbursement rulings, consumer-testing growth metrics, and broader interest-rate and sector-rotation dynamics that affect defensive healthcare valuations.
For traders seeking a data-driven edge alongside fundamental research, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. The tool helps traders discover new opportunities, keep tabs on existing positions, and spot changing trends more efficiently than manual screening. Explore how AI-driven signals can complement your own research process.
A $260 target is achievable in arithmetic terms — a modest 10.6% move above the recent $235 close — but it is not guaranteed. The figure reflects the average of analyst targets above the current price, above an overall consensus that clusters closer to $251, and the wide $232-to-$265 range shows the Street is far from aligned. Strong execution, raised guidance, and a promising advanced-diagnostics pipeline support the bull case, while reimbursement risk, cost inflation, a premium valuation, and the untested $248-$260 resistance zone represent the main hurdles. The third-quarter report and subsequent analyst revisions will be the clearest near-term signals of whether the path to $260 remains open.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, DGX has been closely correlated with LH. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if DGX jumps, then LH could also see price increases.